LY-367,265 is a drug developed by Eli Lilly, which acts as both a potent and selective antagonist at the serotonin 5-HT2A receptor, and also a selective serotonin reuptake inhibitor (SSRI).

It has antidepressant effects in animal studies, reduces glutamate signalling in the brain and increases the analgesic effects of morphine.

[1][2][3] This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.